A$292.40
1.88% yesterday
Australia, Oct 15, 07:10 am CET
ISIN
AU000000PME8
Symbol
PME

Pro Medicus Target price 2025 - Analyst rating & recommendation

Pro Medicus Classifications & Recommendation:

Buy
47%
Hold
47%
Sell
6%

Pro Medicus Price Target

Target Price A$332.34
Price A$292.40
Potential
Number of Estimates 14
14 Analysts have issued a price target Pro Medicus 2026 . The average Pro Medicus target price is A$332.34. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 8 Analysts recommend Pro Medicus to buy, 8 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Pro Medicus stock has an average upside potential 2026 of . Most analysts recommend the Pro Medicus stock at Buy or hold.

Sales and Margin forecast 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Jun '25 2026
Estimates
Revenue Million A$ 220.54 287.27
32.59% 30.26%
EBITDA Margin 78.21% 79.48%
3.13% 1.63%
Net Margin 52.24% 54.50%
4.96% 4.32%

16 Analysts have issued a sales forecast Pro Medicus 2026 . The average Pro Medicus sales estimate is

A$287m
Unlock
. This is
30.26% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
A$306m 38.64%
Unlock
, the lowest is
A$258m 16.96%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 A$221m 32.59%
2026
A$287m 30.26%
Unlock
2027
A$378m 31.60%
Unlock
2028
A$471m 24.49%
Unlock
2029
A$512m 8.82%
Unlock
2030
A$437m 14.65%
Unlock
2031
A$467m 6.94%
Unlock
2032
A$499m 6.66%
Unlock

15 Analysts have issued an Pro Medicus EBITDA forecast 2026. The average Pro Medicus EBITDA estimate is

A$228m
Unlock
. This is
32.38% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
A$261m 51.16%
Unlock
, the lowest is
A$212m 22.73%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 A$172m 36.75%
2026
A$228m 32.38%
Unlock
2027
A$303m 32.68%
Unlock
2028
A$382m 26.07%
Unlock
2029
A$423m 10.81%
Unlock
2030
A$346m 18.29%
Unlock
2031
A$371m 7.21%
Unlock
2032
A$396m 6.94%
Unlock

EBITDA Margin

2025 78.21% 3.13%
2026
79.48% 1.63%
Unlock
2027
80.14% 0.83%
Unlock
2028
81.15% 1.26%
Unlock
2029
82.63% 1.82%
Unlock
2030
79.10% 4.27%
Unlock
2031
79.30% 0.25%
Unlock
2032
79.50% 0.25%
Unlock

15 Pro Medicus Analysts have issued a net profit forecast 2026. The average Pro Medicus net profit estimate is

A$157m
Unlock
. This is
35.87% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
A$173m 50.03%
Unlock
, the lowest is
A$112m 2.80%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 A$115m 39.17%
2026
A$157m 35.87%
Unlock
2027
A$210m 33.87%
Unlock
2028
A$267m 27.43%
Unlock
2029
A$303m 13.60%
Unlock
2030
A$246m 19.03%
Unlock
2031
A$266m 8.12%
Unlock
2032
A$286m 7.51%
Unlock

Net Margin

2025 52.24% 4.96%
2026
54.50% 4.32%
Unlock
2027
55.44% 1.72%
Unlock
2028
56.74% 2.34%
Unlock
2029
59.23% 4.39%
Unlock
2030
56.19% 5.13%
Unlock
2031
56.81% 1.10%
Unlock
2032
57.26% 0.79%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Jun '25 2026
Estimates
Earnings Per Share A$ 1.10 1.50
39.24% 36.36%
P/E 191.51
EV/Sales 104.18

15 Analysts have issued a Pro Medicus forecast for earnings per share. The average Pro Medicus EPS is

A$1.50
Unlock
. This is
36.36% higher
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
A$1.65 50.00%
Unlock
, the lowest is
A$1.07 2.73%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 A$1.10 39.24%
2026
A$1.50 36.36%
Unlock
2027
A$2.01 34.00%
Unlock
2028
A$2.56 27.36%
Unlock
2029
A$2.90 13.28%
Unlock
2030
A$2.35 18.97%
Unlock
2031
A$2.54 8.09%
Unlock
2032
A$2.73 7.48%
Unlock

P/E ratio

Current 260.92 10.78%
2026
191.51 26.60%
Unlock
2027
143.06 25.30%
Unlock
2028
112.27 21.52%
Unlock
2029
98.83 11.97%
Unlock
2030
122.06 23.51%
Unlock
2031
112.89 7.51%
Unlock
2032
105.01 6.98%
Unlock

Based on analysts' sales estimates for 2026, the Pro Medicus stock is valued at an EV/Sales of

104.18
Unlock
and an P/S ratio of
104.90
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 135.70 16.89%
2026
104.18 23.23%
Unlock
2027
79.16 24.01%
Unlock
2028
63.59 19.67%
Unlock
2029
58.43 8.11%
Unlock
2030
68.46 17.16%
Unlock
2031
64.02 6.49%
Unlock
2032
60.02 6.25%
Unlock

P/S ratio

Current 136.64 16.78%
2026
104.90 23.23%
Unlock
2027
79.71 24.01%
Unlock
2028
64.03 19.67%
Unlock
2029
58.84 8.11%
Unlock
2030
68.94 17.16%
Unlock
2031
64.46 6.49%
Unlock
2032
60.43 6.25%
Unlock

Current Pro Medicus Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
WILSONS
Locked
Locked
Locked Sep 16 2025
BELL POTTER SECURITIES
Locked
Locked
Locked Sep 16 2025
MOELIS AUSTRALIA SECURITIES
Locked
Locked
Locked Sep 16 2025
MACQUARIE RESEARCH
Locked
Locked
Locked Sep 04 2025
E&P
Locked
Locked
Locked Aug 14 2025
JEFFERIES
Locked
Locked
Locked Aug 14 2025
MACQUARIE RESEARCH
Locked
Locked
Locked Jul 17 2025
Analyst Rating Date
Locked
WILSONS:
Locked
Locked
Sep 16 2025
Locked
BELL POTTER SECURITIES:
Locked
Locked
Sep 16 2025
Locked
MOELIS AUSTRALIA SECURITIES:
Locked
Locked
Sep 16 2025
Locked
MACQUARIE RESEARCH:
Locked
Locked
Sep 04 2025
Locked
E&P:
Locked
Locked
Aug 14 2025
Locked
JEFFERIES:
Locked
Locked
Aug 14 2025
Locked
MACQUARIE RESEARCH:
Locked
Locked
Jul 17 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today